AMD Invests $20 Million in Absci to Revolutionize AI-Driven Drug Discovery

AMD has made public a strategic investment of $20 million for Absci Corporation, one of the leading generative AI drug discovery companies. In collaboration with the company, they want to create leading biologics using advanced AI technologies, thus giving a concrete example of how AI and healthcare can be integrated in the future.

A Strategic Collaboration to Transform Drug Discovery

AMD and Absci have formed an alliance in which AMD Instinct accelerators and ROCm software are being utilized by Absci to boost its AI-driven workloads. These instruments will be the foundation for Absci’s de novo antibody design model, a way to produce a new antibody sequence without any prior information about the antibody functions.

This partnership shows the demand for AI applications in drug discovery, which has been constantly increasing as Absci uses AMD’s high-performance computing solutions for the following machines:

• Accelerate complex biological modelling
• Optimize performance
• Shorten innovation cycles
• Reduce infrastructure costs

Absci’s aim is being able to deliver biologics to patients more rapidly, so cooperation with AMD is a big step in achieving that commitment.

The World’s First Reverse Folding Model for Antibody Design

Absci and AMD will display the potential of the AMD Instinct accelerator to solve complex biological troubles on January 15 (Pacific Time). The presentation will include Absci’s IgDesign1 model, which is the world’s first reverse-folding model for antibody design and has also been validated in vitro. This novel technology could be a game changer in the way antibodies are designed and can easily lead to faster and also much more efficient drug discovery.

Why This Partnership Matters

With the partnership between AMD and Absci looking like the future of AI in the area of health care, people become aware of the potential of using AI in this field. Being able to blend AMD’s avant-garde software and hardware with Absci’s generative AI Akrima toolkit, aims to reach the following ends:

• Transform the drug discovery process by significantly shirking the time taken and increasing accuracy in biological modelling.
• Bring down the costs that are spent on infrastructure and development of the project.
• To save lives by providing patients with the right treatments, faster.